AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca to buy Esobiotec for upto $1 billion
Drugmaker AstraZeneca on Monday said it will buy biotechnology firm Esobiotec for upto $1 billion.
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market
This biopharmaceutical stock is nearing a buy point of a cup-with-handle base. The post AstraZeneca Stock Nears Buy Point After Long Run In Declining Market appeared first on Investor's Business Daily.
AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster
UBS has reaffirmed its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, with the bank is optimistic about the potential of its blood pressure drug, baxdrostat. The Anglo-Swedish drugs giant is developing baxdrostat as part of a new class of treatments called aldosterone synthase inhibitors (ASIs).
AstraZeneca's Imfinzi success a step towards $80bn revenue aim - analyst
AstraZeneca PLC has edged closer to its aim of generating $80 billion in revenue come 2030 on positive results from a trial of Imfinzi, according to analysts. Shore Capital doubled down on a ‘buy' rating following Friday's update that a combination of the drug and chemotherapy yielded promising results.
AstraZeneca's Imfinzi shows promise in early-stage stomach and oesophageal cancer
A new treatment combining AstraZeneca PLC's (LSE:AZN) drug Imfinzi with chemotherapy has shown promising results for people with early-stage stomach and oesophageal cancer, making it less likely that their cancer will return after surgery. The MATTERHORN trial, a large international study, tested whether adding Imfinzi to standard chemotherapy before and after surgery could improve patient outcomes.
AstraZeneca: A Big Pharma Blue Chip To Buy Now
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. The company is well-positioned for growth over the next few years. AstraZeneca's net debt-to-adjusted EBITDA ratio improved to just 1.5x in 2024.
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
In the closing of the recent trading day, Astrazeneca (AZN) stood at $76.21, denoting a +0.74% change from the preceding trading day.
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for additional hormone treatments.
AstraZeneca gets £2bn boost from breast cancer drug readout
AstraZeneca PLC (LSE:AZN) has seen £2 billion added to its market value after reporting positive results from a breast cancer drug trial. The experimental treatment, camizestrant, improved patient survival without the disease worsening, according to an interim analysis.
AstraZeneca therapy improves survival in late-stage breast cancer trial
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage trial.
3 Magnificent Growth Stocks to Buy Right Now
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value.
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline
AstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate cancer.
